Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis

NCT02994056 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus Infection

Interventions

DRUG: SOF/VEL
DRUG: RBV

Sponsor

Gilead Sciences